A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice

AbbVie

Status: Completed

Conditions: Cancer, Chronic Lymphocytic Leukemia (CLL)

Study type: Observational

Funder types: Industry

Identifiers

NCT04178317

P19-942

Details and patient eligibility

About

This observational study will evaluate the safety and effectiveness of Venetoclax used in routine clinical practice for participants diagnosed with chronic lymphocytic leukemia (CLL).

Enrollment: 14 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants diagnosed with chronic lymphocytic leukemia who have been prescribed Venetoclax for the first time according to the approved label
• Participants (and/or legal representative) who voluntarily agree to participate in this study and sign informed consent

Exclusion criteria

-Participants with contraindications to venetoclax as listed on the approved local label

Trial design

14 participants in 1 patient group

Venetoclax Participants

Description:

Participants receiving venetoclax for chronic lymphocytic leukemia according to the approved local label, and the decision to prescribe Venetoclax is independent from the enrollment into the study.